Stemmatters, based at AvePark, makes progress in NK Cell Isolation

Stemmatters, a company based at AvePark, has reached an important milestone in biotechnology research. Last week, the company’s team successfully completed the first large-scale isolation of primary NK (Natural Killer) cells using the CliniMACS Prodigy® technology. 

Using fresh leukapheresis material, quality control results indicated over 95% purity in the isolated NK cells (CD3-/CD56+), demonstrating the effectiveness of the technique. This advancement marks a significant step forward in the development of immunotherapy treatments. 

Following this success, the company is now focused on the generation of CAR-NK cells, with promising applications in immunotherapy. Stemmatters continues to pursue its goal of providing advanced solutions for the treatment of various diseases. 

The company is making further strides in the field of biotechnology, with expectations of new results soon, as announced in a recent LinkedIn post.